Paul Tudor Jones Opti Nose, Inc. Transaction History

Tudor Investment Corp Et Al

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.77 - $2.93 $82,933 - $137,285	-46,855 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$1.55 - $3.1 $624 - $1,249	-403 Reduced 0.85%	46,855 $76,000
Q3 2021 Nov 15, 2021	BUY	$2.35 - $3.16 $230 - $309	98 Added 0.21%	47,258 $142,000
Q2 2021 Aug 16, 2021	BUY	$2.91 - $3.83 $10,740 - $14,136	3,691 Added 8.49%	47,160 $147,000
Q1 2021 May 17, 2021	BUY	$3.47 - $4.75 $150,837 - $206,477	43,469 New	43,469 $160,000
Q4 2020 Feb 16, 2021	SELL	$3.2 - $4.98 $255,648 - $397,852	-79,890 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.69 - $7.09 $294,794 - $566,420	79,890 New	79,890 $312,000
Q3 2018 Nov 14, 2018	SELL	$12.43 - $29.76 $101,031 - $241,889	-8,128 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$18.75 - $28.46 $152,400 - $231,322	8,128 New	8,128 $227,000

88.3M

Ticker OPTN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 83,277,504
Market Cap $30.8M
Description
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting cort...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.